Publications by authors named "Archie Tse"

Claim this Profile
C
Comprehensive population pharmacokinetic modelling of sugemalimab, an anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I-III studies.
Kun Wang, Chaohsuan Pan, Fengyan Xu, Archie N Tse, Yucheng Sheng

Br J Clin Pharmacol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study.
Antoine Desilets, Justin Lucas, Lisa F Licitra, Sunny Lu, Archie Tse

Target Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma.
Jifang Gong, Ye Guo, Yanqiao Zhang, Yi Ba, Tong Chen, Archie N Tse

Target Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.
Sarwan Bishnoi, Dusan Kotasek, Morteza Aghmesheh, Thomas Yau, Rasha Cosman, Archie N Tse

Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor growth inhibition-overall survival modeling in non-small cell lung cancer: A case study from GEMSTONE-302.
Yucheng Sheng, Shu-Wen Teng, Jingru Wang, Hao Wang, Archie N Tse

CPT Pharmacometrics Syst Pharmacol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer.
Daphne Day, John J Park, Jermaine Coward, Ben Markman, Charlotte Lemech, Archie N Tse

Br J Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can a propensity score matching method be applied to assessing efficacy from single-arm proof-of-concept trials in oncology?
Shu-Wen Teng, Yu-Cheng Su, Ravikumar Pallantla, Madhav Channavazzala, Rukmini Kumar, Archie Tse

CPT Pharmacometrics Syst Pharmacol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STimulator of INterferon Genes Agonism Accelerates Antitumor Activity in Poorly Immunogenic Tumors.
Samanthi A Perera, Johnny E Kopinja, Yanhong Ma, Eric S Muise, Jason Laskey, Archie Tse

Mol Cancer Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST.
Gregory V Goldmacher, Anuradha D Khilnani, Robert H I Andtbacka, Jason J Luke, F Stephen Hodi, Archie Tse

J Clin Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncology phase II proof-of-concept studies with multiple targets: Randomized controlled trial or single arm?
Thomas Jemielita, Archie Tse, Cong Chen

Pharm Stat· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of murine CEACAM1 reveals low expression on CD8 T cells and no tumor growth modulating activity by anti-CEACAM1 mAb CC1.
Robbie L McLeod, Minilik H Angagaw, Toya Nath Baral, Liming Liu, Raymond Joseph Moniz, Archie Tse

Oncotarget· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.
Jo Ishizawa, Kenji Nakamaru, Takahiko Seki, Koichi Tazaki, Kensuke Kojima, Archie Tse

Cancer Res· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development.
Cong Chen, Keaven Anderson, Devan V Mehrotra, Eric H Rubin, Archie Tse

Contemp Clin Trials· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose Finding Versus Speed in Seamless Immuno-Oncology Drug Development.
Kapil Mayawala, Archie Tse, Eric H Rubin, Lokesh Jain, Dinesh P de Alwis

J Clin Pharmacol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.
Marika Ciprotti, Niall C Tebbutt, Fook-Thean Lee, Sze-Ting Lee, Hui K Gan, Archie N Tse

J Clin Oncol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Mark A Dickson, Manish A Shah, Dana Rathkopf, Archie Tse, Richard D Carvajal

Cancer Chemother Pharmacol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
Samuel McNeely, Chiara Conti, Tahir Sheikh, Himali Patel, Sonya Zabludoff, Archie Tse

Cell Cycle· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies.
Archie N Tse, Nian Wu, Dina Patel, Dana Haviland, Nancy Kemeny

Cancer Chemother Pharmacol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer.
Richard D Carvajal, Archie Tse, Manish A Shah, Robert A Lefkowitz, Mithat Gonen

Pancreatology· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780.
Jayasree S Nair, Alan L Ho, Archie N Tse, Jesse Coward, Haider Cheema

Mol Biol Cell· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
9
90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
Archie N Tse, Tahir N Sheikh, Ho Alan, Ting-Chao Chou, Gary K Schwartz

Mol Pharmacol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
Archie N Tse, David S Klimstra, Mithat Gonen, Manish Shah, Tahir Sheikh

Clin Cancer Res· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Sonya D Zabludoff, Chun Deng, Michael R Grondine, Adam M Sheehy, Susan Ashwell, Archie N Tse

Mol Cancer Ther· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting checkpoint kinase 1 in cancer therapeutics.
Archie N Tse, Richard Carvajal, Gary K Schwartz

Clin Cancer Res· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Archie N Tse, Katherine G Rendahl, Tahir Sheikh, Haider Cheema, Kim Aardalen

Clin Cancer Res· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis